Argenx announces european commission approval of vyvgart™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis

Vyvgart is the first neonatal fc receptor (fcrn) blocker approved in europe for the treatment of adults living with generalized myasthenia gravis ( gmg) who are anti-acetylcholine receptor (achr) antibody positive

ARGX Ratings Summary

ARGX Quant Ranking